[A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer].
The combination therapy of lansoprazol (LPZ), amoxycillin (AMPC), and clarythromycin (CAM) (LAC regimen) is one of the most effective eradication regimen of Helicobacter pylori (HP) positive ulcer patients, but the optimal treatment period of this therapy is still pending. The aim of this study was to assess the optimal treatment period of this regimen. One hundred and six patients who diagnosed as HP positive gastric and duodenal ulcer since August 1996 were randomized to one-week treatment group (group 1) or to two-weeks treatment group (group 2): LPZ 30 mg once daily, AMPC 1500 mg twice daily, CAM 800 mg twice daily. Both group received four weeks LPZ treatment (30 mg once daily) following the each combination therapy. The eradication rate of HP was 82.1% (43/56) in group 1 and 85.7% (36/42) in group 2. There was no statistical significant difference between two groups (p = 0.636). Although both treatment regimen was very useful for eradicating HP in the HP positive ulcer patients, one week LAC regimen would be better choice judging from the cost benefit.
Nakagawa
M
M
Department of Gastroenterology, Sapporo Hokuyu Hospital.
Ooishi
M
M
Yoda
Y
Y
Kawamura
N
N
Ooizumi
H
H
Saitou
M
M
Nakagawa
S
S
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000658:Amoxicillin / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D017291:Clarithromycin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000008:administration & dosage; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000382:microbiology; D054328:Proton Pump Inhibitors; D012008:Recurrence; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole